Endothelial progenitor cell-based therapy for pulmonary arterial hypertension

Jin Xiu Yang, Yan Yun Pan, You Yang Zhao, Xing Xiang Wang*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

14 Scopus citations


A growing body of evidence in animal models and clinical studies supports the concept that endothelial progenitor cell (EPC)-mediated therapy ameliorates pulmonary arterial hypertension (PAH) and thus may represent a novel approach to treat it. Conversely, several experimental findings suggest that EPCs may be involved in PAH pathogenesis and disease progression. These discrepant results confuse the application of EPC transplantation as an effective treatment strategy for PAH. To improve the study of EPC transplantation in PAH therapy, it is high time that we resolve this dilemma. In this review, we examine the pathobiological changes of PAH, the characteristics of EPCs, and the underlying mechanisms of EPC effects on PAH.

Original languageEnglish (US)
Pages (from-to)1325-1336
Number of pages12
JournalCell transplantation
Issue number8
StatePublished - 2013


  • Endothelial progenitor cells (EPCs)
  • Mechanisms
  • Pulmonary arterial hypertension (PAH)
  • Transplantation

ASJC Scopus subject areas

  • Biomedical Engineering
  • Cell Biology
  • Transplantation

Fingerprint Dive into the research topics of 'Endothelial progenitor cell-based therapy for pulmonary arterial hypertension'. Together they form a unique fingerprint.

Cite this